Nab-paclitaxel as second-line treatment in advanced biliary cancer

被引：0
|
作者：
Unseld, M. [1 ]
Kornek, G. [2 ]
Werner, S. [2 ]
Guenther, S. [2 ]
Christoph, Z.
Gerald, P.
机构：
[1] Med Univ Vienna, Oncol, Vienna, Austria
[2] MUW, Oncol, Vienna, Austria
来源：
EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷
关键词：
D O I：
10.1016/S0959-8049(16)31215-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2299
引用
收藏
页码：S431 / S432
页数：2
相关论文
共 50 条
  • [21] Second-line treatment of modified FOLFIRINOX or nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma
    Ozaka, Masato
    Sasaki, Takashi
    Yamada, Ikuhiro
    Kanata, Ryo
    Akiyama, Dai
    Katagiri, Tomoko
    Takano, Koichi
    Matsuyama, Masato
    Sasahira, Naoki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [22] Efficacy and safety of nab-paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment for patients with advanced gastric cancer: A single institutional experience
    Okunaka, Mashiro
    Kotani, Daisuke
    Demachi, Ken
    Kawazoe, Akihito
    Yoshino, Takayuki
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [23] Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
    Mita, Naoki
    Iwashita, Takuji
    Uemura, Shinya
    Yoshida, Kensaku
    Iwasa, Yuhei
    Ando, Nobuhiro
    Iwata, Keisuke
    Okuno, Mitsuru
    Mukai, Tsuyoshi
    Shimizu, Masahito
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (06)
  • [24] Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer
    Al-Hajeili, Marwan
    Azmi, Asfar S.
    Choi, Minsig
    ONCOTARGETS AND THERAPY, 2014, 7 : 187 - 192
  • [25] Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
    Masaru Fukahori
    Yoshinobu Okabe
    Mototsugu Shimokawa
    Taiga Otsuka
    Futa Koga
    Yujiro Ueda
    Junichi Nakazawa
    Azusa Komori
    Satoshi Otsu
    Shiho Arima
    Akitaka Makiyama
    Hiroki Taguchi
    Takuya Honda
    Tomoyuki Ushijima
    Keisuke Miwa
    Taro Shibuki
    Kenta Nio
    Yasushi Ide
    Norio Ureshino
    Toshihiko Mizuta
    Kenji Mitsugi
    Tsuyoshi Shirakawa
    Scientific Reports, 13
  • [26] Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer
    Mie, Takafumi
    Sasaki, Takashi
    Okamoto, Takeshi
    Takeda, Tsuyoshi
    Mori, Chinatsu
    Furukawa, Takaaki
    Kasuga, Akiyoshi
    Matsuyama, Masato
    Ozaka, Masato
    Sasahira, Naoki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (12) : 1399 - 1407
  • [27] Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
    Fukahori, Masaru
    Okabe, Yoshinobu
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Koga, Futa
    Ueda, Yujiro
    Nakazawa, Junichi
    Komori, Azusa
    Otsu, Satoshi
    Arima, Shiho
    Makiyama, Akitaka
    Taguchi, Hiroki
    Honda, Takuya
    Ushijima, Tomoyuki
    Miwa, Keisuke
    Shibuki, Taro
    Nio, Kenta
    Ide, Yasushi
    Ureshino, Norio
    Mizuta, Toshihiko
    Mitsugi, Kenji
    Shirakawa, Tsuyoshi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [28] Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response
    Nguyen, Khanh T.
    Kalyan, Aparna
    Beasley, H. Scott
    Singhi, Aatur D.
    Sun, Weijing
    Zeh, Herbert J.
    Normolle, Daniel
    Bahary, Nathan
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2017, 8 (03) : 556 - 565
  • [29] Gemcitabine Plus Nab-paclitaxel as Second-line and Beyond Treatment for Metastatic Pancreatic Cancer: A Single Institution Retrospective Analysis
    Bertocchi, Paola
    Abeni, Chiara
    Meriggi, Fausto
    Rota, Luigina
    Rizzi, Anna
    Di Biasi, Brunella
    Aroldi, Francesca
    Ogliosi, Chiara
    Savelli, Giordano
    Rosso, Edoardo
    Zaniboni, Alberto
    REVIEWS ON RECENT CLINICAL TRIALS, 2015, 10 (02) : 142 - 145
  • [30] Baseline Factors Predictive of the Receipt of Second-Line Chemotherapy After Nab-Paclitaxel Plus Gemcitabine for Patients With Advanced Pancreatic Cancer
    Iede, Kiyotsugu
    Yamada, Terumasa
    Koh, Masahiro
    Ueda, Masami
    Tsuda, Yujiro
    Nakashima, Shinsuke
    Ohta, Katsuya
    Tanida, Tsukasa
    Matsuyama, Jin
    Ikenaga, Masakazu
    Tominaga, Shusei
    PANCREAS, 2022, 51 (03) : 278 - 281
12345